Anti-Cancer Combination Drug Derived from Chinese Herbs

Drug resistance may be developed after prolonged usage of single-target anticancer drug. Combinational drug therapy is one of the most promising strategies in modern anticancer research. Using different combinations of anticancer drugs may exhibit synergistic effects and reduce the drug resistance. This multi-pronged effect could increase therapeutic efficacy.

• This combinational drug consists of Halofuginone (HF) and Artemisinin (ATS), which are compounds extracted from Chinese herbs.
• In the preliminary studies, the combination of HF and ATS showed inhibitory effects on different cancer cells, including colon, breast, liver, gastric and skin cancer. Its efficacy is comparable with, or even higher than that of current anti-cancer drug 5FU.
• After conducting the animal study, it is demonstrated that the drug could provide significant therapeutic effect on colon cancer without severe adverse effects through our observation.

• Patients can benefit from a new and safe anti-cancer drug with higher efficacy and lower toxicity. These potential combinational drugs in TCM might provide alternative options for cancer treatment.

• This pharmaceutical combination can be used in treating colon, breast, liver, gastric and skin cancer.

• China Patent No. ZL 201610006000.1
• US Patent No. US 10,973,823
• Europe Patent Publication No. EP3400936A1
• Hong Kong Patent Publication No. HK 40000274A